中国医学创新2025，Vol.22Issue(4)：1-5,5.DOI:10.3969/j.issn.1674-4985.2025.04.001
卡瑞利珠单抗联合贝伐珠单抗及化疗在非鳞非小细胞肺癌肝转移患者中的疗效
Effect of Camrelizumab Combined with Bevacizumab and Chemotherapy in the Treatment of Patients with Liver Metastasis of Nonsquamous Non-small Cell Lung Cancer
摘要
Abstract
Objective:To investigate the effect of Camrelizumab combined with Bevacizumab and chemotherapy in the treatment of patients with liver metastasis of nonsquamous non-small cell lung cancer.Method:A total of 80 patients with liver metastasis of nonsquamous non-small cell lung cancer in Jiujiang NO.1 People's Hospital from January 2022 to January 2024 were divided into two groups with 40 cases in each group according to the random number table method.The control group was treated with Bevacizumab and chemotherapy,the observation group was treated with Camrelizumab combined with Bevacizumab and chemotherapy.Patients in the two groups were treated for 4 consecutive courses every 21 days as a course of treatment.Then the objective remission rate,disease control rate,toxic side effects rates,T lymphocyte subsets(CD4+and CD4+/CD8+),tumor markers[neuron-specific enolase(NSE),cytokeratin 19 fragments(CYFRA21-1),alpha fetoprotein(AFP)and alkaline phosphatase(ALP)]and apoptosis factors[serum soluble factor-related apoptosis(sFas),soluble factor-related apoptosis ligand(sFasL)and B-cell lymphoma-2(Bcl-2)]before and after the treatment of two groups were compared.Result:The objective remission rate and disease control rate of observation group were significantly higher than those of control group,the toxic side effects rates were significantly lower than those of control group,the differences were all statistically significant(P<0.05).The T lymphocyte subsets,tumor markers and apoptosis factors of two groups before treatment were compared,the differences were not statistically significant(P>0.05),the T lymphocyte subsets of observation group after treatment were significantly higher than those of control group,the tumor markers and apoptosis factors were significantly lower than those of control group,the differences were all statistically significant(P<0.05).Conclusion:The application effect of Camrelizumab combined with Bevacizumab and chemotherapy in the treatment of patients with liver metastasis of nonsquamous non-small cell lung cancer is better,and it is helpful to regulate the body immune and can effectively improve the apoptosis factors.关键词
卡瑞利珠单抗/贝伐珠单抗/非鳞非小细胞肺癌肝转移/毒副反应/细胞凋亡因子Key words
Camrelizumab/Bevacizumab/Liver metastasis of nonsquamous non-small cell lung cancer/Toxic side effect/Apoptosis factors引用本文复制引用
王逸飞,邓建华,刘晓学..卡瑞利珠单抗联合贝伐珠单抗及化疗在非鳞非小细胞肺癌肝转移患者中的疗效[J].中国医学创新,2025,22(4):1-5,5.基金项目
江西省卫生健康委科技计划项目(SKJP202211880) （SKJP202211880）
